Neumora Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Neumora Therapeutics has issued its 2026 proxy statement detailing the upcoming annual meeting of stockholders scheduled for May 27, 2026.
NASDAQ
Neumora Therapeutics is at risk of being delisted from the Nasdaq Global Select Market due to non-compliance with the minimum bid price requirement.
NASDAQ
Neumora Therapeutics announces its 2025 Annual Meeting and seeks stockholder votes on director elections, auditor ratification, stock option repricing, and a potential reverse stock split.
NASDAQ
Neumora Therapeutics is asking stockholders to approve the repricing of certain stock options and a reverse stock split at its upcoming annual meeting.
NASDAQ
DEFA14A: Neumora Therapeutics Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
Neumora Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with proposals including the election of two Class I directors and ratification of Ernst & Young LLP as the independent auditor.
NASDAQ
Neumora Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the independent auditor.